General information about company				
Scrip code	512299			
NSE Symbol	STERLINBIO			
MSEI Symbol				
ISIN	INE324C01038			
Name of the entity	STERLING BIOTECH LIMITED			
Date of start of financial year	01-04-2018			
Date of end of financial year	31-03-2019			
Reporting Quarter	Quarterly			
Date of Report	30-06-2018			
Risk management committee	Not Applicable			

	Annexure I Annexure I to be submitted by listed entity on quarterly basis														
						I. Com	position o	of Board of l	Directors						
					Disclos	ure of notes	on comp	osition of b	oard of d	irectors e	explanatory	Textual Info	ormation(1)		
			Is	there any	change in i	nformation	of board	of directors	compare	e to previ	ous quarter				
Sr	Title (Mr / Ms)	Name of the Director	PAN	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of appointment in the current term	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 25(1) of Listing Regulations)	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)	Notes for not providing PAN	Notes for not providing DIN
1	Mr	Chetan Sandesara	ANIPS6175K	00255671	Executive Director	Not Applicable		15-05-1995			1	0	0		
2	Mr	Nitin Sandesara	AGDPS6471N	00255496	Executive Director	Chairperson		08-01-1991			1	0	0		
3	Mr	Priyadarshanbhai Mehta	AAYPM2209B	01392227	Non- Executive - Independent Director	Not Applicable		01-05-1993		302	1	2	0		
4	Mr	Rajbhusan Dixit	AACPD9215C	00025484	Non- Executive - Independent Director	Not Applicable		15-05-1995		278	1	2	2		

		Annexure I Annexure I to be submitted by listed entity on quarterly basis													
						I. Co	ompositio	on of Board	of Direc	tors					
SI	Title (Mr / Ms)	Name of the Director	PAN	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of appointment in the current term	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 25(1) of Listing Regulations)	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)	Notes for not providing PAN	Notes for not providing DIN
5	Mrs	Mayuriben Patel	ADLPP3199F	00090549	Non- Executive - Independent Director	Not Applicable		25-03-2015		39	1	0	0		

Text Block			
Textual Information(1)	Mr. Vilas Dattatray Joshi Independent Director (Resigned w.e.f. 28-09-2017as per Master Data reflected on MCA Website)		
	This information pertains to number of Directorship and membership/chairmanship held in Sterling Biotech Limited only.		

Annexure 1	
II. Composition of Committees	
Disclosure of notes on composition of committees explanatory	Textual Information(1)
Is there any change in information of committees compare to previous quarter	

	Annexure 1 Text Block	
Textual Information(1)	Mr. Vilas Dattatray Joshi Independent Director (Resigned w.e.f. 28-09-2017as per Master Data reflected on MCA Website)	

Au	Audit Committee Details					
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Remarks	
1	00025484	RAJBHUSHAN OMPRAKASH DIXIT	Non-Executive - Independent Director	Chairperson		
2	01392227	PRIYADARSHANBHAI BHIMBHAI MEHTA	Non-Executive - Independent Director	Member		
3	00507833	VILAS DATTATRAY JOSHI	Non-Executive - Independent Director	Member	Textual Information(1)	

	Audit Committee Details Text Block	
Textual Information(1)	Mr. Vilas Dattatray Joshi Independent Director (Resigned w.e.f. 28-09-2017as per Master Data reflected on MCA Website)	

No	Nomination and remuneration committee					
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Remarks	
1	00025484	RAJBHUSHAN OMPRAKASH DIXIT	Non-Executive - Independent Director	Chairperson		
2	01392227	PRIYADARSHANBHAI BHIMBHAI MEHTA	Non-Executive - Independent Director	Member		
3	00507833	VILAS DATTATRAY JOSHI	Non-Executive - Independent Director	Member	Textual Information(1)	

	Nomination and remuneration committee Text Block
Textual Information(1)	Mr. Vilas Dattatray Joshi Independent Director (Resigned w.e.f. 28-09-2017as per Master Data reflected on MCA Website)

Sta	Stakeholders Relationship Committee					
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Remarks	
1	00025484	RAJBHUSHAN OMPRAKASH DIXIT	Non-Executive - Independent Director	Chairperson		
2	01392227	PRIYADARSHANBHAI BHIMBHAI MEHTA	Non-Executive - Independent Director	Member		
3	00507833	VILAS DATTATRAY JOSHI	Non-Executive - Independent Director	Member	Textual Information(1)	

Stakeholders Relationship Committee Text Block				
Textual Information(1)	Mr. Vilas Dattatray Joshi Independent Director (Resigned w.e.f. 28-09-2017as per Master Data reflected on MCA Website)			

Risl	Risk Management Committee				
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Remarks

Cor	Corporate Social Responsibility Committee				
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Remarks

Ot	Other Committee					
Sr	DIN Number	Name of Committee members	Name of other committee	Category 1 of directors	Category 2 of directors	Remarks

	Annexure 1
Annexure 1	
III. Meeting of Board of Director	'S
	Disclosure of notes on meeting of board of directors explanatory Textual Information(1)

	Text Block		
Textual Information(1)	As already informed to Stock Exchanges, Sterling Biotech Limited (SBL) is in financial distress since an extensive period of time which resulted in Sterling Biotech Limited being admitted into the Corporate Insolvency Resolution Process (CIRP) as per the provisions of the Insolvency and Bankruptcy Code, 2016 (IBC). The application was admitted and the CIRP commenced with effect from June 11, 2018. The undersigned, Mr. Sundaresh Bhat was appointed as the Interim Resolution Professional (IRP) of SBL and subsequently, appointed as the Resolution Professional (RP) by the Committee of Creditors of the Company. As per the provisions of the IBC, the powers of the directors of a Company are suspended and are in-turn vested with the IRP/RP, therefore no meeting of Board of Directors or Committee was held during the quarter.		

	Annexure 1					
IV. Meeting of Committees	IV. Meeting of Committees					
	Disclosure of notes on meeting of committees explanatory	Textual Information(1)				

	Text Block		
Textual Information(1)	As already informed to Stock Exchanges, Sterling Biotech Limited (SBL) is in financial distress since an extensive period of time which resulted in Sterling Biotech Limited being admitted into the Corporate Insolvency Resolution Process (CIRP) as per the provisions of the Insolvency and Bankruptcy Code, 2016 (IBC). The application was admitted and the CIRP commenced with effect from June 11, 2018. The undersigned, Mr. Sundaresh Bhat was appointed as the Interim Resolution Professional (IRP) of SBL and subsequently, appointed as the Resolution Professional (RP) by the Committee of Creditors of the Company. As per the provisions of the IBC, the powers of the directors of a Company are suspended and are in-turn vested with the IRP/RP, therefore no meeting of Board of Directors or Committee was held during the quarter.		

	Annexure 1				
V.	V. Related Party Transactions				
Sr	Subject	Compliance status (Yes/No/NA)	If status is "No" details of non- compliance may be given here.		
1	Whether prior approval of audit committee obtained	NA			
2	Whether shareholder approval obtained for material RPT	NA			
3	Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	NA			

	Annexure 1				
VI	VI. Affirmations				
Sr	Subject	Compliance status (Yes/No)			
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	No			
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	No			
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	No			
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	No			
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 100 listed entities)	NA			
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes			
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	No			
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	No			
9	Any comments/observations/advice of Board of Directors may be mentioned here:	Textual Information(1)			

	Annexure 1		
Sr	Subject	Compliance status	
1	Name of signatory	Rajbhusan Dixit With Authorisation of Sundaresh Bhat Resolution Professional	
2	Designation	Director	

Text Block			
Textual Information(1)	 As already informed to Stock Exchanges Company is unable to comply with the SEBI Regulations within the prescribed time due to following reasons: (a) As already informed to Stock Exchanges, Sterling Biotech Limited (SBL) is in financial distress since an extensive period of time which resulted in Limited being admitted into the Corporate Insolvency Resolution Process (CIRP) as per the provisions of the Insolvency and Bankruptcy Code, 2016 (IBC). The application was admitted and the CIRP commenced with effect from June 11, 2018. The undersigned, Mr. Sundaresh Bhat was appointed as the Interim Resolution Professional (IRP) of SBL and subsequently, appointed as the Resolution Professional (RP) by the Committee of Creditors of the Company. As per the provisions of the IBC, the powers of the directors of a Company are suspended and are in-turn vested with the IRP/RP, therefore no meeting of Board of Directors or Committee was held during the quarter. The going financial distress faced by the Company which resulted in its admission into CIRP leading to sudden change in the management; (b) Search Seizure operations of the Company was conducted by Directorate of Enforcement on 5th August, 2017 and due to some unforeseen circumstances, although the Notice of the 31st AGM which was scheduled to be held on 30th September, 2017 was duly sent, the AGM could not be held on the scheduled date and therefore Statutory Auditors appointment for the Financial Year 2017-18 could not be completed. (c) Investigation is going on in the company by Enforcement Directorate, CBI and Serious Fraud Investigation Office, therefore the employees working with Accounts, Finance and other departments are busy providing the information sought by such investigating agencies. (d) There is no Company Secretary, Chief Financial Officer etc. in the Company. 		

Signatory Details			
Name of signatory	Name of signatory Rajbhusan Dixit With Authorisation of Sundaresh Bhat Resolution Professional		
Designation of person	Director		
Place	Mumbai		
Date	23-11-2018		